Cellular fibronectin is assembled into an
insoluble fibrillar matrix in a complex cell-mediated process. Fibronectin matrix assembly begins when soluble, compact fibronectin
dimers are
secreted from cells, often
fibroblasts. These soluble dimers bind to
α5β1 integrin receptors on the cell surface and aid in clustering the integrins. The local
concentration of integrin-bound fibronectin increases, allowing bound fibronectin
molecules to more readily interact with one another. Short fibronectin
fibrils then begin to form between adjacent cells. As matrix assembly proceeds, the soluble fibrils are converted into larger insoluble fibrils that comprise the
extracellular matrix. Fibronectin's shift from
soluble to insoluble fibrils proceeds when cryptic fibronectin-binding sites are exposed along the length of a bound fibronectin molecule. Cells are believed to stretch fibronectin by pulling on their fibronectin-bound integrin receptors. This
force partially unfolds the fibronectin
ligand, unmasking cryptic fibronectin-binding sites and allowing nearby fibronectin molecules to associate. This fibronectin-fibronectin interaction enables the soluble, cell-associated fibrils to branch and stabilize into an insoluble fibronectin
matrix. A transmembrane protein,
CD93, has been shown to be essential for fibronectin matrix assembly (fibrillogenesis) in human dermal blood endothelial cells. As a consequence, knockdown of CD93 in these cells resulted in the disruption of the fibronectin fibrillogenesis. Moreover, the CD93 knockout mice retinas displayed disrupted fibronectin matrix at the retinal sprouting front. ==Role in cancer==